Top-News
Pharmazeutika Spanien

Grifols SA ADR

Aktie
WKN:  A1C3HH ISIN:  US3984382008 US-Symbol:  GIKLY
4,77 $
-0,025 $
-0,52%
4,2202 € 24.04.25
Depot/Watchlist
Aktienanzahl *
844,37 Mio.
Marktkapitalisierung *
3,57 Mrd. €
Streubesitz
100,00%
Faktor
2
Originalaktie
ES0171996087
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.01.2025

Grifols SA ADR News

26.01.24 - PR Newswire
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF ...
18.01.24 - PR Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF PR Newswire
10.01.24 - PR Newswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF PR Newswire
03.11.22 - PR Newswire
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1 PR Newswire
03.10.22 - PR Newswire
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson PR Newswire
07.09.22 - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Grifols enters into agreement with Canadian Blood Services to accelerate self-​sufficiency in immunoglobulins for Canada PR Newswire
07.09.22 - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Grifols enters into agreement with Canadian Blood Services to accelerate self-​sufficiency in immunoglobulins for Canada PR Newswire
02.03.22 - PR Newswire
Grifols partners with Feeding America® to help address hunger in the U.S.
Grifols partners with Feeding America® to help address hunger in the U.S. - The Grifols Box Out Hunger food drive, in its first year as an official partner of Feeding America®, has a ...
09.02.22 - PR Newswire
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year - Renowned healthcare analyst firm KLAS Research continues to ...
30.11.21 - PR Newswire
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at ...
04.11.21 - PR Newswire
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals - The ALBUTEIN FlexBag, ...
19.10.21 - PR Newswire
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
Grifols and Egypt inaugurate first African plasma-​supply platform, in Cairo, as part of the alliance to attain self-​sufficiency in plasma-​derived medicines PR Newswire
19.10.21 - PR Newswire
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
Grifols and Egypt inaugurate first African plasma-​supply platform, in Cairo, as part of the alliance to attain self-​sufficiency in plasma-​derived medicines - This is the first time the ...
01.06.21 - PR Newswire
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B - The new formulation delivers anti-​hepatitis B ...
19.05.21 - PR Newswire
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona PR Newswire
19.05.21 - PR Newswire
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona PR Newswire
28.04.21 - PR Newswire
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
Grifols and Andorran government will establish world-​class immunology research hub to expand global knowledge of the immune system and develop therapeutics PR Newswire
15.04.21 - PR Newswire
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 - Grifols' new commitment of international units (IU) of blood clotting factors for ...
02.04.21 - PR Newswire
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 Grifols ...
25.03.21 - PR Newswire
Grifols Procleix UltrioPlex E und Procleix Babesia Assays erhalten CE-Kennzeichnung
Grifols Procleix UltrioPlex E und Procleix Babesia Assays erhalten CE-​Kennzeichnung PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »